Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity

Scandinavian Journal of Rheumatology

Volumn 43, Issue 1, 2014, Pages 43-48

  Korkosz, M ^a   Gasowski, J ^a   Leszczynski P ^b   Pawlak Bus K ^b   Jeka, S ^c   Siedlar, M ^a   Grodzicki, T ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Department of Rheumatology and Connective Tissue Diseases   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DICKKOPF 1 PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; WNT3A PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOKE ANKYLOSING SPONDYLITIS SPINE SCORE;

ADULT; ANTIRHEUMATIC AGENTS; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; WNT3A PROTEIN;

EID: 84892986448     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.805241     Document Type: Article

References (20)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90. (Pubitemid 46590387)
2. Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65. (Pubitemid 40852884)
3. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
4. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
5. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
6. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis: mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009;11:221.
7. Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006;1068:19-25. (Pubitemid 43824133)
8. Lories R, Luyten F. Bone morphogenetic proteins in destructive and remodelling arthritis. Arthritis Res Ther 2007;9:207-14.
9. Maksymowych WP. Biomarkers in spondyloarthritis: from pathophysiology to disease assessment. Joint Bone Spine 2012;79:4-6.
10. Duan ZH, Pan FM, Zeng Z, Zhang TC, Wang S, Li GX, et al. The FCGR2B rs10917661 polymorphism may confer susceptibility to ankylosing spondylitis in Han Chinese: a case-control study. Scand J Rheumatol 2012;41:219-22.
11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
12. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008;10:R125.
13. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009;60:3257-62.
14. Wendling D, Cedoz JP, Racadot E. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. Joint Bone Spine 2008;75:559-62.
15. Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis 2012;15:358-65.
16. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010;62:150-8.
17. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010;21:294-301.
18. Spiro AS, Beil FT, Baranowsky A, Barvencik F, Schilling AF, Nguyen K, et al. BMP-7-induced ectopic bone formation and fracture healing is impaired by systemic NSAID application in C57BL/6-mice. J Orthop Res 2010;28:785-91.
19. Arikawa T, Omura K, Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004;200:400-6. (Pubitemid 39006932)
20. Vane SJ. Differential inhibition of cyclooxygenase isoforms: an explanation of the action of NSAIDs. J Clin Rheumatol 1998;4:s3-10.